HCFA announces FDG payment rate
The nuclear medicine community has reason for celebration following the Health Care Financing Administration's June 3 announcement of a national average payment for PET scans. According to ADAC Laboratories of Milpitas, CA, HCFA stated that its Medicare
The nuclear medicine community has reason for celebration following the Health Care Financing Administration's June 3 announcement of a national average payment for PET scans. According to ADAC Laboratories of Milpitas, CA, HCFA stated that its Medicare reimbursement rate would be $1980 for the technical elements of PET imaging, including the isotope F-18 fluorodeoxyglucose (FDG).
The rate pertains to both dedicated PET scanners and coincidence detection gamma cameras. Physician fees will be billed separately and compensated similarly to SPECT scans. HCFA has asked its carriers to apply the rate to all scans since Jan. 1, 1998, the date it made its first statement regarding coverage for lung cancer indications.
The announcement establishes a minimum level of medical care for those covered by Medicare insurance, and makes it unlikely that private carriers will refuse appropriate requests for PET scans, according to executives at cyclotron network operator P.E.T.Net Pharmaceutical Services in Norcross, GA.
Could AI-Powered Abbreviated MRI Reinvent Detection for Structural Abnormalities of the Knee?
April 24th 2025Employing deep learning image reconstruction, parallel imaging and multi-slice acceleration in a sub-five-minute 3T knee MRI, researchers noted 100 percent sensitivity and 99 percent specificity for anterior cruciate ligament (ACL) tears.
Meta-Analysis Shows Merits of AI with CTA Detection of Coronary Artery Stenosis and Calcified Plaque
April 16th 2025Artificial intelligence demonstrated higher AUC, sensitivity, and specificity than radiologists for detecting coronary artery stenosis > 50 percent on computed tomography angiography (CTA), according to a new 17-study meta-analysis.
Can CT-Based AI Radiomics Enhance Prediction of Recurrence-Free Survival for Non-Metastatic ccRCC?
April 14th 2025In comparison to a model based on clinicopathological risk factors, a CT radiomics-based machine learning model offered greater than a 10 percent higher AUC for predicting five-year recurrence-free survival in patients with non-metastatic clear cell renal cell carcinoma (ccRCC).
